Table 2:
Response to Decitabine and Survival
| Characteristic | Upfront Setting (N=72) | Relapsed/Refractory Setting (N=36) | Relapse After Upfront Decitabine Induction (N=8) |
|---|---|---|---|
| Response - no. (%) | |||
| Complete remission (CR) | 12 (16.7) | 3 (8.3) | 0 (0) |
| Complete remission with incomplete count recovery (CRi) | 14 (19.4) | 6 (16.7) | 0 (0) |
| Overall response rate (CR+CRi) | 26 (36.1) | 9 (25.0) | 0 (0) |
| Median overall survival (OS) - days (mo.) | 198 (6.6) | 143 (4.8) | 50 (1.7) |
| 30-day mortality - no. (%)a | 4 (5.6) | 3 (8.3) | 0 (0) |
| 60-day mortality - no. (%)b | 14 (19.4) | 9 (25.0) | 5 (62.5) |
| Response with Respect to Cytogenetics | |||
| Characteristic | Upfront Setting, Intermediate Cytogenetics (N=32) |
Relapsed/Refractory Setting, Intermediate Cytogenetics (N=19) | |
| Response - no. (%) | |||
| CR, intermediate cytogenetics | 4 (12.5) | 2 (10.5) | |
| CRi, intermediate cytogenetics | 5 (15.6) | 3 (15.8) | |
| Overall response rate (CR+CRi), intermediate cytogenetics | 9 (28.1) | 5 (26.3) | |
| Median OS, intermediate cytogenetics - days (mo.) | 282 (9.4) | 238 (7.9) | |
| Characteristic | Upfront Setting, Unfavorable Cytogenetics (N=37) | Relapsed/Refractory Setting, Unfavorable Cytogenetics (N=16) | |
| Response - no. (%) | |||
| CR, unfavorable cytogenetics | 6 (16.2) | 1 (6.3) | |
| CRi, unfavorable cytogenetics | 9 (24.3) | 3 (18.8) | |
| Overall response rate (CR+CRi), unfavorable cytogenetics | 15 (40.5) | 4 (25.0) | |
| Median OS, unfavorable cytogenetics - days (mo.) | 161 (5.4) | 53 (1.8) | |
a
Of the 30-day mortality group, 71 upfront patients were evaluable for mortality.
b
Of the 60-day mortality group, 70 upfront patients were evaluable for mortality.